NIH Starts Study of Allergic Reactions to Covid-19 Vaccines

April 7, 2021, 1:38 PM

The NIH is starting a clinical trial to determine whether people who are highly allergic or have a mast cell disorder are at increased risk for an immediate, systemic allergic reaction to the Moderna or Pfizer-BioNTech Covid-19 vaccines.

  • Investigators will examine the biological mechanism behind the reactions and whether a genetic pattern or other factors can predict who is at most risk
  • The Phase 2 trial, called Systemic Allergic Reactions to SARS-CoV-2 Vaccination, is sponsored and funded by NIAID
  • The study team will enroll 3,400 adults ages 18 to 69 years at up to 35 academic allergy-research centers nationwide
  • NOTE: ...

To read the full article log in.

Learn more about a Bloomberg Law subscription.